239 related articles for article (PubMed ID: 35936689)
1. Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation.
Bergamini M; Dalla Volta A; Caramella I; Bercich L; Fisogni S; Bertoli M; Valcamonico F; Grisanti S; Poliani PL; Bertagna F; Berruti A
Front Oncol; 2022; 12():937713. PubMed ID: 35936689
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Addressing the need for more therapeutic options in neuroendocrine prostate cancer.
Kemble J; Kwon ED; Karnes RJ
Expert Rev Anticancer Ther; 2023 Feb; 23(2):177-185. PubMed ID: 36698089
[TBL] [Abstract][Full Text] [Related]
4. Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation.
Vargas Ahumada J; González Rueda SD; Sinisterra Solís FA; Pitalúa Cortés Q; Torres Agredo LP; Miguel JR; Scavuzzo A; Soldevilla-Gallardo I; Álvarez Avitia MA; Sobrevilla N; García Pérez FO
Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741197
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer.
Weber M; Hadaschik B; Ferdinandus J; Rahbar K; Bögemann M; Herrmann K; Fendler WP; Kesch C
Eur Urol Focus; 2021 Mar; 7(2):279-287. PubMed ID: 33483289
[TBL] [Abstract][Full Text] [Related]
6. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
[No Abstract] [Full Text] [Related]
7. Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPC.
Laarhuis BI; Janssen MJR; Simons M; van Kalmthout LWM; van der Doelen MJ; Peters SMB; Westdorp H; van Oort IM; Litjens G; Gotthardt M; Nagarajah J; Mehra N; Privé BM
Clin Genitourin Cancer; 2023 Oct; 21(5):e352-e361. PubMed ID: 37164814
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implications of dual tracer PET/CT: PSMA ligand and [
Michalski K; Ruf J; Goetz C; Seitz AK; Buck AK; Lapa C; Hartrampf PE
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2024-2030. PubMed ID: 33336265
[TBL] [Abstract][Full Text] [Related]
9. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
10. TheraP: a randomized phase 2 trial of
Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID
BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341
[TBL] [Abstract][Full Text] [Related]
11. Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer.
Fankhauser CD; Poyet C; Kroeze SGC; Kranzbühler B; Schüler HIG; Guckenberger M; Kaufmann PA; Hermanns T; Burger IA
World J Urol; 2019 Mar; 37(3):457-467. PubMed ID: 30030659
[TBL] [Abstract][Full Text] [Related]
12. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
[TBL] [Abstract][Full Text] [Related]
13. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
14. Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer.
Vlachostergios PJ; Niaz MJ; Sun M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST
Front Oncol; 2021; 11():630589. PubMed ID: 33680970
[TBL] [Abstract][Full Text] [Related]
15. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
[TBL] [Abstract][Full Text] [Related]
16. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
[TBL] [Abstract][Full Text] [Related]
17. Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [
Hartrampf PE; Lapa C; Serfling SE; Buck AK; Seitz AK; Meyer PT; Ruf J; Michalski K
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503080
[TBL] [Abstract][Full Text] [Related]
18. Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.
Chen J; Qi L; Tang Y; Tang G; Gan Y; Cai Y
Front Cell Dev Biol; 2022; 10():958180. PubMed ID: 36036001
[TBL] [Abstract][Full Text] [Related]
19. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
[TBL] [Abstract][Full Text] [Related]
20. The current status of prostate cancer treatment and PSMA theranostics.
Uemura M; Watabe T; Hoshi S; Tanji R; Yaginuma K; Kojima Y
Ther Adv Med Oncol; 2023; 15():17588359231182293. PubMed ID: 37424944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
